In vivo therapeutic effect of IMC-EB10 in EOL-1 xenograft leukemia model. (A) NOD-SCID mice (10 per group) bearing EOL-1 leukemia were treated intraperitoneally with indicated doses of antibodies 3 times weekly. Mouse survival was monitored daily. Compared with control IgG, treatment with 500 μg, 250 μg, and 100 μg IMC-EB10 all significantly prolonged survival of the mice. No effect was seen for 10 μg IMC-EB10, suggesting that the antileukemic effect of IMC-EB10 was dose dependent. This graph is representative of results from 3 similar experiments. (B) Mice bearing EOL-1 leukemia were treated with IMC-EB10 (500 μg) for 20 days. Mice were killed, and bone marrow cells were analyzed by immunohistochemical staining with antihuman CD45 antibody. The number of leukemia cells was significantly decreased by IMC-EB10 treatment. Original magnification, × 200.